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Introduction 
 
The key to the astonishing progress of open heart surgery during the last 5 
decades has been cardiopulmonary bypass (CPB) by an extracorporeal 
circulation (1). The concept is simple: the patients blood returning to the 
right atrium through the superior and inferior caval vein is removed from 
the body by the use of one or several cannula and diverted into a reservoir. 
All the blood is pumped back via an arterial line after it has been 
oxygenated and the carbon dioxide removed. 
Ever since its invention, the deleterious effects of extracorporeal circulation 
on the blood and its constituents have been recognised. In contrast to the 
pathways of the blood within the body, the extracorporeal circuit is not lined 
with endothelial cells. The passage of the patient’s blood through the circuit 
affects nearly all physiologic processes within the body (2). Today it is 
widely believed that activation of the blood cells and plasma protein 
systems, which are delineated in Table 1, are causally connected to the 
whole body inflammatory reaction, described by Kirklin et al (3). The 
resulting injury to the body and its organs is variable in its extent, but some 
degree of impaired function of kidneys, lungs, and the brain is usually 
apparent (4). 
 
 
Table 1: Cells and Plasmatic Systems Activated by Cardiopulmonary 
Bypass. Modified from Edmunds et al.  (5) 
 
cells plasmatic systems 
platelets contact 
endothelial cells coagulation 
neutrophils fibrinolytic 
monocytes complement 
lymphocytes  
 
 
Activation of the clotting cascade via the intrinsic system (Figure 1) is 
initiated by the contact of blood with the foreign surface of the 
extracorporeal circuit. Activated monocytes adhere to the perfusion circuit 
and express tissue factor which probably further activates coagulation (6). In 
addition, high levels of tissue factor within the surgical wound lead to 
activation of the extrinsic system of coagulation (Figure 1) (7). These 
reactions would ultimately lead to clotting of the patients blood within the 
extracorporeal circuit by fibrin formation and platelet activation. Therefore 
the use of heparin as an anticoagulant during CPB is a condition sine qua 
non. However, heparin is far from being an ideal anticoagulant. Heparin  
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does not inhibit the coagulation cascade completely (Figure 1). At least F 
XII, F XI, and prekallikrein are activated, and high-molecular-weight 
kininogen is cleared (8). Thus markers of fibrin formation can be detected in 
most patients during and early after CPB, and fibrin emboli can occur (9). 
In addition to the activation of the clotting cascade, it has been shown that 
CPB leads to significant fibrinolysis (10). 
Immediately after the initiation of CPB, there is a rapid increase in the 
circulating levels of tissue-plasminogen activator (11). Tissue- plasminogen 
activator, which is stored and released by endothelial cells, catalyses the 
fibrinolytic system leading to a lysis of blood clots. The fibrinolytic cascade 
is depicted in Figure 2. 
The cellular system participating in the process of blood clotting is the 
blood platelets. It has been shown repeatedly that alteration of platelet 
function is responsible for some of the effects of CPB on the human body 
(12). 
The net clinical effect of CPB on coagulation, fibrinolysis, and blood 
platelets is an impairment of blood clotting in some patients if not all (13). 
Bleeding is responsible for a considerable part of the morbidity associated 
with open heart surgery. Roughly 3-5 % of patients need more than 10 units 
of blood transfusions to compensate for abnormal blood loss (13). 3-14 % of 
patients require reoperation for bleeding (14). Surgeons and intensivists 
involved in the postoperative care of these patients are well aware of the fact 
that the disposition for bleeding varies greatly. Many variables may 
influence the individual patients disposition for bleeding.  
The aim of this study is to investigate some of the mechanisms involved in 
impairment of blood coagulation during CPB with particular reference to 
evaluation of platelet function. In addition, methods to predict the amount of 
the blood loss will be explored. 
 14
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Study Objectives 
 
Paper I 
In this prospective study the effects of CPB on platelet surface antigens 
associated with platelet activation, aggregation, and adhesion and the 
platelet volume were measured. In 20 patients, the expression of the GPIIb-
IIIa, Ib, 53, and P-selectin were measured using flow cytometry in platelet 
rich plasma before and after in vitro stimulation with adenosine 
diphosphate. 
 
Paper II 
Aprotinin, a serin protease inhibitor, is known to reduce blood loss 
following CPB by limiting hyperfibrinolysis. Its influence on circulating 
platelets is uncertain. In this prospective trial we investigated activation, 
adhesion, and aggregation receptors on the platelet surface in 20 patients 
who underwent elective coronary artery bypass grafting. These patients 
were randomly assigned to receive either a high dose of aprotinin or 
placebo. Flow cytometry was performed to determine platelet activation (P - 
selectin, GP 53), adhesive (GPIb), and aggregatory (GPIIb-IIIa) receptors 
on circulating platelets, before, during, and after CPB. 
 
Paper III 
In this study the potential of centrifugal blood pumps for saving blood was 
investigated. 120 patients scheduled for elective coronary artery bypass 
grafting were entered into a prospective randomised trial comparing 
different perfusion strategies. In group I standard roller pumps were used. 
Centrifugal blood pumps were used in group II In group III roller pump 
were employed and aprotinin was given. The rationale was to test whether 
the potential blood saving effect of centrifugal pumps was comparable to the 
effect of using aprotinin as a supplement to a standard perfusion circuit. In 
addition the effect of different pumps on platelet function was investigated. 
 
Paper IV 
In this prospective study, the time dependent effects of extracorporeal 
circulation and heparin-mediated effects on platelet surface antigens in vitro 
were investigated using whole blood flow cytometry. 
Blood samples were drawn prior to and following CPB in 89 patients. The 
response of surface antigen expression GPIIb-IIIa, P-selectin, and GPIb was 
measured. 
 
Paper V 
The predictive value of parameters possibly associated with blood loss 
following CPB was investigated in a prospective study. 
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The data of 89 patients scheduled for elective heart surgery with CPB were 
included and blood samples drawn before and after surgery. Chest tube 
drainage was measured hourly until removal of drains. 
Activation of coagulation and fibrinolysis, routine clotting tests and 
expression of platelet surface antigens, using flow cytometry, were 
analysed. 
 
 
Paper VI 
The suitability of two commercially available in vitro bleeding tests (IVBT), 
the PFA-100® and the Hepcon® HMS to predict blood loss following 
operations with CPB was compared to conventional coagulation studies. 
In 40 patients a blood sample was taken before and after CPB to measure 
platelet count, prothrombin time, aPTT, d-dimers, fibrinogen, and PFA-
100® and Hepcon® HMS data. The postoperative blood loss was recorded 
hourly until removal of drains. 
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Material and Methods 
 
All studies were approved by the institutional review board. Informed 
consent was obtained from all patients. Patients were referred to the 
University Hospital of Regensburg, Germany for elective coronary artery 
bypass grafting. Patients subjected to emergency procedures were excluded. 
Patients receiving platelet-active medication for less than ten days before 
the operation, patients on intravenous heparin and patients with unstable 
angina were excluded from the study. None of the patients investigated had 
a history suggestive of a haemostatic disorder. Details of operations, 
anaesthesia and postoperative regimen were similar in all studies. Details 
are outlined below. 
 
Anaesthesia and Surgical Procedures 
All patients had anaesthesia induced with fentanyl, etomidate, and 
pancuronium, maintained with oxygen, isoflurane and fentanyl. An arterial 
line was placed into the left femoral or radial artery. A central venous line 
and a Swan-Ganz catheter (Baxter Deutschland, Unterschleißheim, 
Germany) were placed into the internal jugular vein. Heparin (Liquemin N, 
Hoffman La Roche, Germany, 375 IU/kg) was used as anticoagulant before 
cannulation. The kaolin activated clotting time (ACT) was maintained over 
480 seconds during CPB by additional doses of heparin, if required. CPB 
was performed at a minimal temperature of 31°C with a nonpulsatile flow 
ranging from 2.4 to 2.6 l/min/m2 with a roller pump (Stöckert Instrumente, 
Munich, Germany). In paper III a centrifugal pump was used with a BP 80 
pump head (Biomedicus, Medtronik, Bad Homburg, Germany) in group II. 
The extracorporeal circuit was primed with 1,500 ml of Ringer’s solution 
and 100 ml of mannitol 10%. 7,500 IU of heparin were added to the pump 
prime. A membrane oxygenator (Maxima II, Medtronik, Bad Homburg, 
Germany) was used in all cases. Heparin was completely neutralised after 
discontinuation of CPB with protamin sulphate (Protamin, Hoffman La 
Roche, Germany). Additional protamin sulphate was given, if the ACT was 
above 120 s. Surgical haemostasis was achieved using a standardised 
protocol. Blood remaining in the extracorporeal circuit was returned to the 
patient in the early postoperative period. The cardiotomy reservoir was used 
to collect mediastinal blood loss. The chest tubes were connected to the 
reservoir before closure of the chest. Chest tube drainage was recorded 
hourly until removal of drains on the morning following surgery. 
Mediastinal shed blood was not reinfused. Transfusion of packed red cells 
was considered below an haemoglobin value of 9 g/dl, particularly in 
bleeding patients. Fresh frozen plasma and platelet transfusions were given, 
if the blood loss via the mediastinal drains was more than 200 ml for 3 
consecutive hours. 
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Analysis of Platelet Function 
Flowctometry 
Blood was collected in commercially available vials (Sarstedt, Nümbrecht, 
Germany) containing ethylenediaminetetraacetic acid anticoagulant, for 
measurement of haemoglobin concentration, haematocrit value, platelet 
count, and platelet volume, using a Technicon H3 hematology analyzer 
(Bayer Diagnostics, Tarrytown, USA). Another blood sample collected in 
trisodium citrate was drawn for flow cytometry. In papers I, II, and III 
platelet function was assessed by using flow cytometry in platelet rich 
plasma. To obtain further information on platelet haemostatic function, the 
response of the surface antigens to adenosine diphosphate (ADP) in vitro 
was performed in all samples. 
Blood samples were collected in trisodium citrate and processed 
immediately. Platelet rich plasma was prepared by centrifugation at 150 g 
for 15 minutes. The platelet rich plasma was diluted in phosphate buffered 
saline (Biochrom, Berlin, Germany) containing 1 mg/ml bovine serum 
albumin (PBS/BSA) and the platelet count was adjusted to approximately 
20,000 platelets/µl. The dilution is necessary to ensure analysis of individual 
platelets. 20 µl of the platelet suspension was incubated at room temperature 
for 10 minutes with 5 µl of ADP (110 µmol/l) (DiaAdin, DiaMed, Cressier 
sur Morat, Switzerland) or PBS/BSA. Thereafter all samples were incubated 
for 5 minutes at room temperature with one of the following fluorescein 
isothiocyanate (FITC)-labelled monoclonal antibodies: anti-glycoprotein 
(GP)IIb/IIIa (cluster of differentiation (CD) 41a, P2), anti-GPIb (CD 42b, 
SZ2), anti-GP53 (CD 63, CLB-Gran/12), and anti-P-selectin (CD 62P, 
CLB-Thromb/6), all from Immunotech (Marseille, France). Samples were 
diluted with 300 µl of PBS/BSA and analysed in a Becton Dickinson 
FACScan flow cytometer (Becton Dickinson, San José, CA, USA). A Lysis 
II software was used for measurements. 10,000 platelets were acquired in 
list mode at a flow rate of 12 µl/minute, 500 - 1,000 particles/second. 
 
In papers IV and V the in vitro response of platelets to stimulation was 
analysed by flow cytometry in a dual colour whole blood assay. Platelets 
were identified by their high and constitutive expression of glycoprotein 
(GP) IIb/IIIa (CD 41, integrin αIIbβ3). This method allows analysis in diluted 
whole blood independent of variations in platelet concentration and avoids 
artefactual stimulation during centrifugation. Platelet activation is quantified 
based on the increased surface expression of P-selectin (CD 62) following 
degranulation of α-granules (15) and at the same time the decreased surface 
expression of GPIb, the receptor for von Willebrand factor (vWF), 
following internalization into the open canalicular system (16). The 
simultaneous surface recruitment of GPIIb-IIIa, the platelet receptor for 
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fibrinogen (17), serves as a further independent indicator of platelet 
activation (18). To obtain further information on platelet haemostatic 
function, the response of the surface antigens to submaximal stimulation 
with ADP or thrombin receptor agonist peptide-6 (TRAP-6) in vitro was 
performed in all samples. In addition the in vitro heparin response on 
platelet surface antigen expression in the preoperative sample was tested by 
in vitro incubation with heparin. 
In vitro stimulation with ADP or TRAP-6 causes an increased expression of 
GPIIb-IIIa and P-selectin and a decrease in GPIb expression. A blood 
sample collected in trisodium citrate was processed immediately to perform 
measurements of platelet surface antigen expression, using whole blood 
flow cytometry. 100 µl of the sample were diluted in 900 µl of phosphate 
buffered saline (Biochrom, Berlin, Germany) containing 1 mg/ml bovine 
serum albumin (Sigma, Deisenhofen, Germany) (PBS/BSA). 20 µl of this 
solution were incubated for 10 minutes at room temperature with PBS/BSA 
or 15 µmol/l of ADP. Thereafter a saturating concentration of Phycoerythrin 
(PE) - labelled anti – GPIIb-IIIa (CD41, P2) and one of the following FITC 
- labelled antibodies: anti – GPIb (CD 42b, SZ2), anti - P-selectin (CD 62, 
CLB - thromb/6) were added and incubated for 5 minutes (all antibodies 
from Immunotech, Marseille, France) at room temperature. Then 1 ml of 
cold PBS/BSA was added and all samples were analysed with an Ortho 
Cytoron Absolute flow cytometer (Ortho Diagnostic Systems, 
Neckargmünd, Germany). The PE fluorescence of the brightly expressed 
antigen GPIIb-IIIa was used as a threshold for the detection of platelets in 
the diluted whole blood. The analysis of the PE fluorescence of GPIIb-IIIa 
in the dual combination, with the only dimly expressed antigen P-selectin 
and the brighter GPIb on the FITC channel, allowed the control of the 
critical compensation of FITC overlap into the PE channel. 10,000 platelets 
were acquired in list mode at a low sample flow rate (0.25 µl/sec) and 
sheath flow rate (100 µl/sec). For data analysis platelets were identified 
automatically, using the AutoGate function of the Immunocount II software 
(Otho Diagnostic Systems, Neckargmünd, Germany), followed by 
calculation of mean FITC and PE fluorescence. The calibration of the 
instrument was controlled for each set of experiments using fluorescent 
standard beads (Polysciences, Eppelheim, Germany), which are similar to 
the stained platelets in light scatter and fluorescence intensities. 
 
PFA-100® and the platelet-activated clotting time (PACT) (Paper VI) 
The PFA-100® and the platelet-activated clotting time (PACT) in the 
Hepcon® HMS were used as platelet function test in paper VI. 
The PFA-100® (DADE Diagnostika, Unterschleißheim, Germany) is based 
on the test proposed by Kratzer and Born (19). A citrated whole blood 
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sample is introduced into a disposable test cartridge. The blood is aspirated 
through a glass capillary into a cup. There it comes into contact with an 
ADP or epinephrine coated membrane with a central aperture (150 µm 
diameter). During aspiration of blood, platelets adhere to the aperture. 
During the course of the measurement a stable platelet plug forms that 
eventually occludes the aperture. The time from beginning until occlusion of 
the aperture is defined as the ”closure time”. This closure time was shown to 
be indicative of the platelet function in the sample (20). 
The PACT in whole blood is measured with the Hepcon® HMS (Medtronic, 
Düsseldorf, Germany). The test was performed in duplicate. Platelet 
procoagulant activity was measured by determining the kaolin-activated 
clotting time (ACT) with platelet activating factor (PFA) added to the 
cartridge. The PACT values were expressed as the percent maximum 
response (21). 
 
Additional Methods Used in Individual Papers 
Paper I 
Blood samples were taken just prior to heparinization while purse string 
sutures were applied to the aorta (A), before cannulation and after heparin 
was allowed to recirculate (B), at one hour of CPB (C), and one hour after 
discontinuation of CPB (D). A serum sample was taken for total protein 
value, creatinine. The platelet count was corrected for haemodilution 
according to the method described by Harker et al. (12). 
 
Paper II 
Patients were randomly allocated to one of two groups. In group APR, 
aprotinin (Trasylol, Bayer AG, Leverkusen, Germany) was given: 2 x 106 
IU with induction of anaesthesia, 2 x 106 IU were added to the pump prime, 
and 5 x 105 IU per hour were infused continuously during CPB. Group 
CON served as the control. Blood samples were taken just prior to 
heparinization (A), at one hour of CPB (B), and one hour after completion 
of CPB (C) from the arterial line. Another blood sample was taken prior to 
heparinization (A), one hour after discontinuation of CPB (C), and six hours 
following discontinuation of CPB (D) for measurement of the specific 
degradation product of fibrinogen, d-dimers, using a latex immunoassay. 
 
Paper III 
In group I, a conventional standard roller pump (Stöckert Instrumente, 
Munich, Germany) was used. This group served as a control. In group II, 
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CPB was conducted with a centrifugal blood pump with a BP 80 pump head 
(Biomedicus, Medtronik, Bad Homburg, Germany). Group III individuals 
were placed on CPB using a roller pump (Stöckert Instrumente, Munich, 
Germany) and aprotinin (Trasylol, Bayer AG, Leverkusen, Germany) was 
given: 2 x 106 I.E. with induction of anaesthesia, 2 x 106 I.E. were added to 
the pump prime, and 5 x 105 I.E. per hour were infused continuously during 
CPB. The conduction of CPB was otherwise identical in all groups. A blood 
sample for serum levels of creatinine, free haemoglobin, full blood count, 
total protein, lactic dehydrogenase (LDH), aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) was taken during and after the 
operation. In a subset of 10 individuals per group, further blood samples 
were taken for investigation of thrombocyte function using flow cytometry 
as described above. 
 
Paper V 
Blood samples were drawn from all patients on the day prior to surgery by 
venipuncture in the right antecubital fossa and immediately after arrival of 
the patient in the intensive care unit following surgery from an indwelling 
arterial line. Besides all samples described in the general section, another 
sample was collected in trisodium citrate (Sarstedt, Nümbrecht, Germany) 
for measurement of prothrombin time (PT), activated partial thromboplastin 
time (aPTT), thrombin time (TT) and antithrombin (AT), using a 
chromogenic assay. Fibrinogen was measured using the Clauss method. The 
specific degradation products of fibrinogen, d-dimers, were measured 
quantitatively using a latex immunoassay. Enzyme linked immunosorbent 
assays were used to measure tissue plasminogen activator (t-PA), thrombin 
antithrombin complex (TAT) and prothrombin fragment 1+2 (F1+2). 
Chromogenic substrates were employed to determine α2-antiplasmin. 
Another sample was collected in citrate-theophylline-adenosine-
dipyridamole-tubes (Diatube H vials, Boehringer Mannheim, Mannheim, 
Germany) and stored on ice for measurement of platelet factor 4 (PF4), 
using an enzyme linked immunsorbent assay.  
 
Paper VI 
Blood samples for evaluation were taken during anaesthesia before CPB 
was instituted and at the end of surgery. A full blood count was performed 
and the prothrombin time, the activated partial thromboplastin time (aPTT), 
d-dimers, and fibrinogen were determined. One sample each was taken to 
measure the closing time in the PFA-100® and the platelet-activated clotting 
time (PACT) in the Hepcon® HMS. 
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Statistical Analysis 
SPSS software for Windows® with an advanced statistics module was used 
on a personal computer for statistical analysis. 
The student's t-test for paired data was used to test for statistical significance 
between groups of normally distributed data. If more than two groups were 
compared, Bonferroni correction was used (paper I). The U test according to 
Wilcoxon, Mann and Whitney was used as a nonparametric test. One way 
analysis of variance (ANOVA) with repeated measures was performed for 
all variables that were measured at three or more different time points. The 
student’s t-test for paired data was used as a post hoc test. The level of 
significance was adjusted according to the Bonferroni correction. The 
correlation of the preoperative and postoperative variables was tested 
according to Pearson. Spearman’s rank correlation was used for non-
parametric data (paper V). In paper V further analysis was performed with 
multiple regressions using a linear regression model with blood loss as the 
dependent variable. Independent variables were included stepwise into the 
regression equation using score statistics at 0.05 level for entry. The 
correlation coefficient (r2 value) was recorded. The student’s t-test and the 
Wilcoxon-Mann-Whitney test were used to test for significant differences 
between subgroups that were formed for further analysis as indicated in the 
results section. Multiple logistic regression was performed to determine the 
predictive value of different parameters for blood loss between ”bleeders” 
and ”non-bleeders” as defined in the results section. 
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Summary of Results 
 
Paper I 
Heparinization resulted in a significant increase of GP 53 and P-selectin and 
a significant decrease of GPIb expression. During and following 
cardiopulmonary bypass GPIIb-IIIa and GPIb were significantly decreased. 
Similarly, the expression of the activation markers was reduced 
significantly. The mean platelet volume decreased significantly from 8.5 + 
0.7 fl at baseline to 7.9 + 0.8 fl at the end of the study period (p < 0.017). 
 
Paper II 
Aprotinin had neither a significant effect on platelet activation nor on 
adhesive and aggregatory receptors. Plasma levels of d-dimers were 
measured before and after CPB to assess fibrinolytic activity. d-dimers 
following CPB (0.6 + 0.5mg/l vs. 1.4 + 0.9 mg/l) and chest tube drainage 
(363 + 119 ml  vs. 858 + 333 ml, p<0.05) were significantly less in the 
aprotinin group. 
 
Paper III 
There was no significant difference between group I and II with respect to 
free haemoglobin, lactic dehydrogenase, serum bilirubin, platelet surface 
GPIIb-IIIa and P-selectin, chest tube drainage, use of blood products, length 
of stay in intensive care, time on ventilator, and postoperative mortality. 
Aprotinin reduced chest tube drainage (840 + 335 ml vs. 513 + 409 ml) and 
use of blood products significantly.  
 
Paper IV 
A significant correlation between the duration of extracorporeal circulation 
and the postoperative response of GPIIb-IIIa, GPIb, and P - selectin was 
found. Postoperative P-selectin and GPIb expression stimulated with ADP 
correlated to blood loss. Heparin in vitro significantly reduced GPIb 
expression (278.6 ± 47.5 versus 259.1 ± 36.8). 
Heparin as well as the duration of extracorporeal circulation independently 
correlated with phenotypic changes of platelets following extracorporeal 
circulation. 
 
Paper V 
A significant correlation was found between blood loss and variables of 
coagulation (activated partial thromboplastin time, fibrinogen, prothrombin 
fragment 1+2, d-dimers, and thrombin antithrombin complex) and platelet 
count. In addition a correlation between blood loss and platelet count, GPIb 
and P-selectin expression on platelets was found. Intraoperative variables 
had also an influence on bloos loss (use of the internal thoracic artery, cross 
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clamp time). In a multiple regression model, GPIb expression on platelets, 
platelet count, use of the internal thoracic artery and d-dimers were 
significantly associated with blood loss. Logistic regression analysis 
revealed that postoperative values of GPIb and d-dimers predicted an 
increased blood loss with a positive predictive value of 73 % and a negative 
predictive value of 91 %. 
 
Paper VI 
A significant correlation was found between total blood loss (250-1750 ml) 
and the preoperative PFA-100® (r=0.41, p=0.022), the preoperative platelet 
count (r=0.42, p=0.007), the preoperative D-dimer concentration in the 
plasma (r=0.41, p=0.01), and duration of CPB (r=0.35, p=0.044). There was 
no significant correlation between blood loss and the Hepcon® HMS system. 
There appears to be a great variability in individual results. 
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Discussion 
 
Flow Cytometry – Measurement of Platelet Function 
A great number of laboratory tests have been designed to test platelet 
function. Many of them have been used to investigate the platelet function 
defect of CPB. As early as 1980 several of these tests were available to 
Harker et al.: platelet aggregometry, plasma levels of β-TG, PF4, platelet 
content of ADP and ATP, and morphometric analysis of platelet granule 
number (12). Some of these, i.e. plasma contents of β-TG and PF4, are only 
indirect markers of platelet function and may simply indicate that 
degranulated platelets have left the circulation, or could be due to artefacts 
during measurement (22, 23). Aggregometry has been used extensively to 
investigate platelet function (12, 24-26). However aggregometry is 
semiquantitative and has standardization problems (27). 
We used single colour flow cytometry in platelet rich plasma from 
peripheral blood samples before, during, and after CPB in papers I, II, and 
III. A dual colour assay was used in papers IV and V. The advantage of flow 
cytometry over other methods is that it allows for analysis of surface 
antigens on individual platelets, independent of platelet-to-platelet 
interaction and platelet concentration (28). Within the flow cytometer, 
platelets are hydrodynamically focussed to a serial cell flow that crosses a 
laser beam. At the time of intercept with the laser beam, each cell generates 
forward light scatter, dependent on cell size, and right angle light scatter, 
dependent on cell granularity. Thus different cell populations are 
characterised, providing a typical two-dimensional plot shape. Additional 
information is gained by fluorescent light emission impulses from laser light 
excitation of prestained cells. This is achieved by allowing platelet surface 
epitopes to react with monoclonal antibodies that were conjugated with 
fluorochrome dyes. We chose to mark surface antigens that are known to be 
involved in platelet aggregation, such as GPIIb-IIIa, or platelet activation, 
such as P-selectin or GP 53. Flow cytometry was shown to be advantageous 
over other ex vivo methods and is particularly suited to investigate platelet 
function (28). 
In papers I, II, and III the assay was performed in platelet rich plasma to 
simplify the experimental protocol. The authors are aware of the fact that 
the preparation of platelet rich plasma may lead to platelet activation (29). 
Provided a standardised method is used, this should result in a constant 
error, i.e. the expression of platelet surface markers may be artificially 
increased. All samples were carefully drawn and processed immediately, 
according to the protocol described in the methods section. Attention was 
paid to consistently minimise platelet activation during preparation of the 
blood sample. 
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Other scientists fixed platelets after blood samples were drawn to eliminate 
ex vivo platelet activation  (30, 31). However, we chose to stimulate 
platelets in vitro with ADP to obtain further information on platelet 
haemostatic function as suggested by Michelson (28). Thus platelets were 
not fixed. 
Fixation of samples following stimulation and prior to measurement, as 
suggested by Kestin et al. (22), was unnecessary since all our samples were 
measured immediately after their preparation. 
 
 
Mechanisms of Abnormal Bleeding After CPB 
Haemodilution 
Simple haemodilution during CPB in itself leads to a reduction of 
coagulation factors by approximately 50% (13). However, the resulting 
levels are usually high enough to maintain the coagulation process (12). 
Thus it is not surprising that most studies were unable to find a correlation 
between the level of soluble coagulation factors and blood loss (32). 
 
Platelet Dysfunction 
Impaired platelet function is an important cause of abnormal bleeding. 
Platelet activation and subsequent impairment of function starts already with 
the administration of heparin. 
High dose heparin was shown to prolong the bleeding time and other 
parameters of platelet function before CPB was started (33). In addition, we 
found an in vivo effect of heparin on platelet surface antigen expression, 
namely GPIb (paper I). This was confirmed by others, using flow cytometry  
(22) or platelet aggregometry (34, 35). In vitro experiments (paper IV) 
confirmed these findings: an effect of heparin on the expression of GPIb but 
not GPIIb-IIIa and P-selectin was shown. Moreover the in vitro response 
correlated significantly with the ratio of pre- and postoperative GPIb 
expression. This indicates that heparin may reduce GPIb expression on 
circulating platelets.  
 
Despite the use of high doses of heparin sufficient thrombin is generated to 
induce a marked increase in circulating TAT complexes after CPB starts 
(36, 37). In paper V, we describe an increase in circulating TAT complexes 
and F1+2 reflecting a significant activation of the coagulation cascade. The 
activation of coagulation and the resulting thrombin formation leads to 
platelet activation early during CPB (38). 
Other agonists, such as activated complement, plasmin, platelet-activating 
factor, serotonin, epinephrin, as well, contribute to platelet activation (33, 
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38). This activation results in a change of shape of circulating platelets with 
formation of pseudopods, especially at the beginning of CPB (23). 
Activated platelets adhere to the surface of the artificial circuit and thus 
leave the circulation (39). This and blood haemodilution are the major 
causes of thrombocytopenia following CPB. Thrombocytopenia, however, 
contributes to abnormal bleeding, since platelet count is inversely correlated 
to blood loss (paper V). 
 
The functional status of platelets remaining within the circulation may be 
described by their expression of platelet surface antigens. In this respect, we 
found a significant decrease in GPIIb-IIIa on the surface of circulating 
platelets during and after CPB. Therefore, we conclude that the fibrinogen 
receptor plays a role in the platelet function defect of CPB. Most studies 
performed in this field are in accordance with our results (31, 40). 
Also GPIb was significantly reduced during CPB with and without in vitro 
stimulation with ADP. Several authors obtained similar results using 
different methods, including whole blood cytometry (25, 31, 41, 42). Some 
studies found no effect of CPB on GPIb (22, 43). This lead to a continued 
debate on whether the functional defect is intrinsic or extrinsic to the 
platelet (22). Likewise show studies on platelet activation (P-selectin and 
GP53) inconsistent results. Some report activation of platelets by CPB (31, 
44), just as we did (paper I), others found no significant change before and 
during CPB (22, 30, 40, 42). Reports on increased numbers of platelet-
leukocyte aggregates during CPB support our results, because the formation 
of these aggregates is mediated via P-selectin on the platelet surface (45). It 
appears that the effect of CPB on platelet surface antigens is time dependent 
(paper IV). We found a direct correlation of the duration of CPB with 
platelet adhesion receptor phenotype in vitro and the difference of pre- and 
postoperative platelet count. Moreover the degree of platelet activation 
(expression of GPIb and P-selectin) by in vitro stimulation with ADP after 
CPB correlated significantly with postoperative blood loss. 
 
The results described in the preceding paragraph and the observation of a 
continued reduction of mean platelet volume (MPV) during CPB (paper I), 
support the following hypothesis:  
Circulating platelets are activated by heparin in vivo before CPB. During 
the initial phases of CPB some platelets are lost from the circulation by 
adherence to artificial surfaces (30, 38). After the release of the aortic cross-
clamp a significant blood activation takes place with increasing 
thrombin/antithrombin III complex levels and other markers of clotting and 
fibrinolysis (37). The administration of protamin reverses the inactivation of 
thrombin by heparin. This leads to further consumption of circulating 
platelets. The surface expression of GP53 and P-selectin of in vitro 
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stimulated platelets is therefore lowest shortly after CPB (paper I). It 
appears that mainly large and thus more active platelets disappear, 
particularly towards the end of CPB. Less activated and smaller platelets 
remain within the circulation. This mechanism may contribute to the platelet 
function defect of CPB. Our hypothesis is also supported by findings of 
Huang et al., who reported a progressive decrease of ristocetin-induced 
platelet agglutination during and after CPB (41). 
 
Hyperfibrinolysis 
Only recently has hyperfibrinolysis been recognised to be an important 
contributor to the development of abnormal bleeding following open heart 
surgery (46, 47). Again heparin seems to play a role before CPB by 
stimulating release of plasmin from cell surfaces (48). It is of note that 
plasmin and d-dimer interact with platelets and thus possibly contribute to 
platelet dysfunction  (49). 
In paper V we describe our data on hyperfibrinolysis confirming activation 
of the fibrinolytic system (d-dimers, t-PA, and α2-antiplasmin). We found a 
positive correlation between  indicators of hyperfibrinolysis and blood loss, 
confirming the importance of the described mechanisms. In addition d-
dimers are a useful in predicting the amount of  blood loss. 
 
Other Factors 
Several other factors associated with CPB may contribute to abnormal blood 
loss. Obviously administration of drugs acting on platelets or fibrinolytics 
have an influence, but their effect is not necessarily exclusive to the use of 
CPB. Further discussion will thus be omitted. 
Skin temperature and hypothermic CPB were shown to be an important 
determinant of bleeding (50, 51). This is probably mediated by the effect of 
temperature on platelet function (52). 
Coagulation disorders in individual patients may contribute to abnormal 
bleeding as well. This requires special attention in terms of screening and 
preoperative as well as postoperative treatment (53). 
 
Prediction of Abnormal Bleeding 
As described above, the influence of CPB on coagulation, fibrinolysis and 
blood platelets is thought to be responsible for the abnormal bleeding seen 
in a number of patients undergoing heart surgery. It seems logical to assume 
that the degree of impairment of the systems involved has an influence on 
the amount of the blood loss following the operation. Thus prediction of the 
amount of blood loss should be feasible by measuring the values of a 
predefined set of parameters.  
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As expected, an activation of the fibrinolytic system (d-dimers, t-PA, and 
α2-antiplasmin) was found in a group of 89 patients undergoing operations 
with CPB. This was significantly correlated to postoperative blood loss 
(paper V). 
Parameters associated with blood platelets, i.e. platelet count and expression 
of GPIb and P-selectin on the platelet surface also showed a statistically 
significant correlation. The best correlation with postoperative blood loss of 
all parameters was found for use of the internal thoracic artery as a bypass 
graft (r = 0.433). This is probably a consequence of the larger wound 
surface that results from internal thoracic artery harvesting. Routine clotting 
tests such as aPTT, however, were not significantly correlated to blood loss 
in our study. In contrast, Gravlee et al. (54) found a statistically significant 
correlation between mediastinal drainage and routine clotting tests such as 
aPTT, PT, and TT. Others found no association of clotting factors with 
abnormal bleeding (32). 
Several investigators used aggregometry or hemostatometry to predict blood 
loss following heart surgery (26, 55). However, the predictive value of these 
tests was low (26).  
According to our working hypothesis, a combination of parameters 
reflecting different aspects of blood clotting system should have a higher 
chance of yielding clinically relevant data. In multiple regression analysis 
the best model for prediction of blood loss was achieved by the combination 
of postoperative platelet count, platelet surface expression pre- and 
postoperatively, as well as the use of ITA and d-dimers. When aiming at 
discriminating”bleeders” from ”non-bleeders”, the combination of 
postoperative values for d-dimers and GPIb expression yielded the highest 
predictive value. Bleeders were defined as patients who bled more than 
mean plus one standard deviation. Therefore the combination of both 
parameters seems particularly helpful to exclude non-surgical causes in 
bleeding patients since specificity and the negative predictive value were 
high. This may aid the identification of individuals who require surgical 
reexploration. 
 
The usefulness of commercially available tests of platelet function was 
analysed too (paper VI). The correlation coefficient of blood loss with in 
vitro bleeding tests was not superior to the results of simple tests of 
coagulation such as platelet count, d-dimers, or duration of CPB. In fact, the 
PACT using the Hepcon® HMS was not significantly correlated to blood 
loss at all. In contrast, Ereth et al. found a significant correlation of blood 
loss and PACT in a larger group of patients (21). However their PACT 
result as well was not superior to other tests of coagulation (21). 
The reasons for the somewhat disappointing results of these simple in vitro 
platelet function tests are probably related to the mechanisms of the 
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haemostatic defect of CPB. Fibrinolysis for example is not directly tested 
for in the PFA-100® or the Hepcon® HMS. Moreover haematocrit, platelet 
count, and leukocyte count were shown to influence closure times of the 
Thrombostat 4000® (56, 57), an in vitro bleeding test similar to the PFA-
100®. 
 
The Prevention of Abnormal Bleeding 
Obviously the prevention of abnormal blood loss following open heart 
surgery starts with taking a clinical history on previous episodes of 
abnormal bleeding and some screening tests. Relative common disorders, 
such as von Willebrand disease, factor VIII deficiency are often known to 
the patient. Many others can be detected on routine blood tests, such as 
thrombocytopenias. Nevertheless represent life threatening bleeding 
episodes in patients with haemostatic disorders a therapeutic challenge. 
Prevention or treatment, respectively, consists of transfusion of platelets, 
transfusion of clotting factors, plasmapheresis, pretreatment with steroids, or 
use of desmopressin. Non-specific treatment with drugs that have been 
shown to reduce blood loss, such as aprotinin, aminocarbocyclic acid and 
other antifibrinolytics may be advisable. Patients on platelet active 
medication carry an increased risk of abnormal bleeding (58). If possible, 
these drugs should be stopped prior to surgery. 
 
Prophylactic Drug Treatment 
Prophylactic drug treatment is an efficient and well characterised strategy to 
reduce postoperative blood loss generally and to reduce the incidence of 
abnormal bleeding in particular. Salzman et al. and Royston et al. were the 
first to show the efficacy of desmopressin and aprotinin, respectively, in 
reducing blood loss in cardiac surgery (59) (60). Many others have 
confirmed their results (41, 42, 61). Probably the most prominent among 
these prophylactic drugs is aprotinin. The presumed mode of action of this 
serine protease inhibitor is mediated by its anti-fibrinolytic activity and its 
influence on platelet function (61-63). The action of aprotinin on 
hyperfibrinolysis probably through direct inhibition of plasmin is undoubted 
and well documented  (64) (61, 62, 65). Our results (paper II),  that show  
significantly diminished levels of d-dimers in patients treated with aprotinin, 
are in accordance with this. 
The effect of aprotinin on platelets is less clear. A preservation of the 
platelet surface expression of GPIb or even an increase in GPIb by aprotinin 
has been claimed by some (38, 41, 63, 66). We were unable to confirm these 
findings using flow cytometry (paper II).  
Other scientists, using several techniques, found no influence of aprotinin 
on platelet GPIb (67-69). These contradicting results may be a consequence 
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of  methodological problems of studies using radioisotope labelling 
techniques (41, 63, 67), that require several steps of centrifugation and 
filtration which possibly influence the expression of platelet surface 
antigens (22). 
GPIIb-IIIa expression was unaffected by aprotinin in our study. This is in 
accordance with previous studies on GPIIb-IIIa expression (66, 70). In 
contrast, Lavee et al. claimed that aprotinin protected platelet aggregation 
during CPB, using electron microscopy (71). However, bubble oxygenators 
instead of modern membrane oxygenators were used in this study and CPB 
was conducted at a much lower body temperature (27+4°C). Both factors 
are known to influence platelet function significantly (50, 72), rendering 
comparison with our data difficult. 
A recent metaanalysis revealed that other antifibrinolytic drugs, such as 
tranexamic acid and aminocarbocyclic acid, were equally effective in 
reducing blood loss at much lower costs, compared to aprotinin (73). Being 
a potent serine protease inhibitor aprotinin has additional effects on other 
enzyme systems, such as kallikrein (74). This may lead to an attenuation of 
the whole-body inflammatory response of CPB. The drug may also 
attenuate neutrophil activation and myocardial damage during aortic cross-
clamping (75). However, the clinical significance of these findings in 
routine cases is by no means proven. In contrast, serious concerns have been 
raised following reports of increased early occlusion rates of bypass grafts 
in patients receiving aprotinin (76). However, also this hypothesis has not 
been proven definitely. Nevertheless, the use of prophylactic drug treatment 
is usually only recommended in cases with a particular high risk of 
abnormal bleeding, i.e. patients on platelet active medication (emergency 
cases) or with surgical risks such as reoperation. 
 
Platelet Anaesthesia 
Platelet anaesthesia is an appealing concept that refers to a strategy to 
preserve platelet during CPB by temporarily inhibiting platelets during the 
period of extracorporeal perfusion. If the inhibitor is removed immediately 
after CPB, larger numbers of functionally adequate platelets are available to 
normalise bleeding time and to reduce postoperative blood losses. 
Substances suggested in experimental and clinical studies are prostacyclin 
or GPII-IIIa inhibitors (77, 78). Due to significant side effects and the 
insufficient control of drug action, this concept has not yet found its way 
into routine clinical practice. 
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Blood Conservation Methods 
A substantial number of blood conservation methods have been proposed to 
reduce bleeding and handle abnormal blood loss. Autologous blood 
donation, normovolaemic haemodilution before CPB, salvage and 
transfusion of shed mediastinal blood during and following the operation are 
appropriate and generally accepted procedures. These methods have proven 
their efficacy in numerous studies and are routine in many centres (79). 
 
Use of Centrifugal Blood Pumps 
High level of shear stress can produce platelet aggregation and promote 
shedding of microparticles from the platelet plasma membrane  (80). 
Therefore it seems obvious that the use of pumps within the perfusion 
circuit may contribute to abnormal bleeding. In a search for less traumatic 
blood pumps, centrifugal pumps where introduced. Indeed centrifugal 
pumps have been shown to reduce trauma to the blood components in a 
number of studies performed in vitro and clinically (81-83). Although the 
advantages of centrifugal pumps in long-term extracorporeal circulation are 
well established, the blood saving potential of these pumps in routine 
cardiac surgery is still controversial (82, 84-87). 
Our study (paper III) was the first to compare different blood pumps to 
aprotinin with regard to blood loss and other variables in a prospective 
randomised trial. 
There was no significant difference in postoperative blood loss in our 
patients, which is in contrast to the findings of Lynch et al. (87). However 
our findings are in accordance with data published by others (88, 89). The 
centrifugal pump had little influence on laboratory data that would indicate 
significant blood trauma, such as LDH and free haemoglobin. These 
findings are equally supported by published data (86, 89, 90). 
In contrast, it is well known that centrifugal pumps are advantageous in long 
term extracorporeal circulation (extracorporeal lung support, ventricular 
assist) (82, 84, 85). 
In paper III, a comparison of the expression of platelet surface antigens and 
platelet count between roller pumps and centrifugal blood pumps was done. 
Platelet count and the expression of platelet surface antigens was not 
significantly different for the study groups compared to controls. The initial 
drop in platelet count during and after ECC in all groups is probably caused 
by haemodilution. These results support the findings of Driessen et al. (90). 
Our data on platelet surface antigens support the hypothesis that centrifugal 
blood pumps do not improve platelet function in routine CPB. 
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Heparin Coated Equipment 
Heparin can be attached to certain extracorporeal perfusion materials by 
ionic or covalent bonds.  
Heparin coated equipment reduces complement and granulocyte activation 
(91-93) and reduces circulating cytokines IL-6 and IL-8 (94). Heparin-
coated perfusion circuits attenuate activation of platelets in some studies 
(95) but not others (93, 96). Different heparin coated systems have been 
used clinically together with reduced doses of systemic heparin (usually 150 
units/kg) and activated clotting times around 280 s in routine bypass surgery 
(93, 94, 96). Authors reported 4.5 to 24 percent reductions in postoperative 
blood loss (93, 94, 96). However, concern has been raised about the safety 
of reducing the systemic heparin dose, which seems to be a prerequisite to 
actually reduce blood loss when using coated systems. The evidence is 
empirical and specific for first-time myocardial revascularization 
operations; extrapolation of this experience to different patients and 
different protocols may or may not be safe. Nevertheless heparin coated 
equipment is routinely used in a number of centres and new promising 
coating techniques are under development. 
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Conclusions 
 
I. Flow cytometry allows for analysis of surface antigens on individual 
platelets, independent of platelet-to-platelet interaction and platelet 
concentration and is particularly suited to investigate platelet 
function during CPB. 
 
II. Abnormal bleeding following CPB is largely related to heparin, 
platelets and fibrinolysis. We suggest that a loss of larger and more 
activated platelets from the circulation contributes substantially to 
the platelet function defect of cardiopulmonary bypass. 
 
III. Parameters indicating hyperfibrinolysis and platelet dysfunction are 
useful to predict abnormal bleeding. Commercially available in vitro 
platelet function tests are significantly correlated to postoperative 
blood loss but have little clinical value. 
 
IV. Prophylactic drug treatment is an efficient strategy to reduce 
postoperative blood loss. Aprotinin reduces the fibrinolytic response 
to CPB, but has no measurable influence on the expression of 
platelet surface antigens. 
 
V. The use of centrifugal blood pumps for routine heart surgery offers 
no advantage over conventional roller pumps with respect to platelet 
function, blood loss, free haemoglobin, or LDH. 
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